Earnings Call · Q1 FY2022·2022-02-08

Q1 22EPS -33.33%·Rev n/aQ4 21EPS -2.52%·Rev n/aQ3 21EPS +7.75%·Rev n/aQ2 21EPS -12.37%·Rev n/a⚠ consensus missing

ENANTA PHARMACEUTICALS INC ENTA

Jennifer Viera — Investor Relations

Jay Luly — President and Chief Executive Officer

Paul Mellett — Chief Financial Officer

−2.9%1d on move date−3.7% vs SPY3d+2.7%5d−3.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ENTA calls or request research access.

More ENTA calls Browse calls Request research access